Literature DB >> 34306451

The effect of comfort nursing on liver function and nursing satisfaction of patients with liver cirrhosis.

Mei Cui1, Meihong Sun2, Lu Bu3.   

Abstract

OBJECTIVE: The goal of the present study was to explore and analyze the effect of comfort care on liver function and nursing satisfaction of patients with liver cirrhosis.
METHOD: A total of 122 patients with liver cirrhosis addmitted to our hospital from June 2018 to June 2020 were equally divided into a general care group (GC) and a comfort care group (CC) according to the principle of randomization. Routine care intervention was given in the GC group, and the CC group received both comfort care intervention and routine care intervention. The care effects regarding liver function and nursing satisfaction, etc. were analyzed and compared between the two groups.
RESULTS: After care, both SAS score and SDS score in the two groups decreased, and the CC group had better scores of SAS and SDS as compared to the GC group (P<0.05). After care, the ALT and AST levels of the two groups all decreased. In the GC group, the ALT and AST demonstrated significantly better levels than those in the GC group (P<0.01). After care, each aspect in the CC group had better scores as compared to that in the GC group (P<0.05). After care, in the CC group, all the physiology, psychology, society and other index scores were significantly better than those in the GC group (P<0.05). Patients in the CC group had higher treatment compliance scores in comparison to patients in the GC group [(89.86±6.45) vs (64.46±13.75), P<0.01]. In the CC group, the nursing satisfaction (93.44%) was significantly higher than 78.69% in the GC group (P<0.01).
CONCLUSION: Comfort care is a preferred nursing method for patients with liver cirrhosis in terms of elimination of negative emotions, recovery of liver function, quality of life improvement, treatment compliance, and nursing satisfaction. AJTR
Copyright © 2021.

Entities:  

Keywords:  Comfort care; liver cirrhosis; liver function; nursing satisfaction

Year:  2021        PMID: 34306451      PMCID: PMC8290692     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  22 in total

Review 1.  Hepatopulmonary syndrome-attributed extreme hypoxemia and polycythemia revealing liver cirrhosis.

Authors:  Alexandre Nuzzo; Raphael Dautry; Claire Francoz; Damien Logeart; Bruno Mégarbane
Journal:  Am J Emerg Med       Date:  2018-09-26       Impact factor: 2.469

2.  Effect of curcumin supplementation on disease severity in patients with liver cirrhosis: A randomized controlled trial.

Authors:  Masoud Nouri-Vaskeh; Aida Malek Mahdavi; Hossein Afshan; Leila Alizadeh; Mohammad Zarei
Journal:  Phytother Res       Date:  2020-02-03       Impact factor: 5.878

3.  Two alcoholic liver cirrhosis patients developed diabetic ketoacidosis after SGLT2 inhibitors-prescription.

Authors:  Hung-Yu Chao; Edy Kornelius
Journal:  J Formos Med Assoc       Date:  2020-07-18       Impact factor: 3.282

4.  Histologic severity of liver cirrhosis: A key factor affecting surgical outcomes of hepatocellular carcinoma in patients with portal hypertension.

Authors:  Ke-Shuai Dong; Bin-Yong Liang; Zun-Yi Zhang; Er-Lei Zhang; Guang Yang; Shu-Li Xia; Xiao-Ping Chen; Zhi-Yong Huang
Journal:  Asian J Surg       Date:  2019-02-16       Impact factor: 2.767

5.  Comparison of Hospital Anxiety and Depression Scale (HADS) and Zung Self-Rating Anxiety/Depression Scale (SAS/SDS) in Evaluating Anxiety and Depression in Patients with Psoriatic Arthritis.

Authors:  Tao Yue; Qiting Li; Rongsheng Wang; Zhaoyi Liu; Mengru Guo; Fengmin Bai; Zhanming Zhang; Weifeng Wang; Yahui Cheng; Haijun Wang
Journal:  Dermatology       Date:  2019-08-21       Impact factor: 5.366

6.  An Argument for Vitamin D, A, and Zinc Monitoring in Cirrhosis.

Authors:  Andree H Koop; Omar Y Mousa; Ly Elaine Pham; Juan E Corral-Hurtado; Surakit Pungpapong; Andrew P Keaveny
Journal:  Ann Hepatol       Date:  2018-10-16       Impact factor: 2.400

7.  Extrahepatic manifestations and healthcare expenditures of non-alcoholic fatty liver disease in the Medicare population.

Authors:  Mehmet Sayiner; Tamoore Arshad; Pegah Golabi; James Paik; Freba Farhat; Zobair M Younossi
Journal:  Hepatol Int       Date:  2020-04-16       Impact factor: 6.047

8.  Assessment of lenvatinib treatment for unresectable hepatocellular carcinoma with liver cirrhosis.

Authors:  Shohei Komatsu; Yoshihiko Yano; Keitaro Sofue; Masahiro Kido; Motofumi Tanaka; Kaori Kuramitsu; Masahide Awazu; Hidetoshi Gon; Atsushi Yamamoto; Hiroaki Yanagimoto; Hirochika Toyama; Yuzo Kodama; Takamichi Murakami; Takumi Fukumoto
Journal:  HPB (Oxford)       Date:  2020-03-29       Impact factor: 3.647

9.  Impact of cardiac function, refractory ascites and beta blockers on the outcome of patients with cirrhosis listed for liver transplantation.

Authors:  Valerio Giannelli; Olivier Roux; Cédric Laouénan; Pauline Manchon; Floriane Ausloos; Delphine Bachelet; Pierre-Emmanuel Rautou; Emmanuel Weiss; Richard Moreau; Alexandre Mebazaa; Alain Cohen-Solal; François Durand; Claire Francoz
Journal:  J Hepatol       Date:  2019-10-14       Impact factor: 25.083

10.  Prevalence of Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis: A Cross-Sectional, Clinicoepidemiological, Multicenter, Nationwide Study in India: The PREDICT Study.

Authors:  Sahaj Rathi; Madhu Chopra; Gourdas Chouduri; Praveen Sharma; Kaushal Madan; Mohinish Chhabra; Ramesh R Rai; Anurag Govil; Asokananda Konar; Mahesh Goenka; Manoj Agarwal; Jayanta Mukherjee; Vinay Thorat; Sanjay Salunkhe; Philip Abraham; Aabha Nagral; Ajay Jhaveri; Naresh Bhat; Joy Varghese; Arun R S; Deevaguntla C Reddy; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2018-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.